Skip to main content
Clinical Trials/NCT02180074
NCT02180074
Completed
Not Applicable

Measurement of Distinct Biological Pools of Hydrogen Sulfide in Women With Cardiovascular Disease

Louisiana State University Health Sciences Center Shreveport1 site in 1 country137 target enrollmentSeptember 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiovascular Disease
Sponsor
Louisiana State University Health Sciences Center Shreveport
Enrollment
137
Locations
1
Primary Endpoint
Free Sulfide, Bound Sulfide and Acid Labile Sulfide
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Cardiovascular disease which includes coronary artery disease and peripheral artery disease remains the leading cause of death among women in the United States. The impact of cardiovascular in women was not recognized by clinicians for a long time. It is now evident that, women suffer the consequences of cardiovascular at rates at least as high as those observed in men but there are still major gaps in our understanding this disease in women. Hydrogen sulfide (H2S), a gaseous mediator plays an important role in the cardiovascular system. Research has demonstrated it's critical role in animal ischemia reperfusion models. Hydrogen sulfide exists in distinct biological pools in blood. Recently, the Kevil lab has pioneered the development of new analytical techniques for accurate measurement of all biological pools of H2S. By measuring these distinct pools of H2S in women with and without cardiovascular disease the investigators hope to further understanding of role of H2S in pathophysiology of cardiovascular disease. This research will help to assess the ability of H2S and its distinct biological pools to potentially be a diagnostic marker or a therapeutic target for cardiovascular disease.

Registry
clinicaltrials.gov
Start Date
September 2013
End Date
May 7, 2017
Last Updated
4 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
Louisiana State University Health Sciences Center Shreveport
Responsible Party
Principal Investigator
Principal Investigator

Christopher Kevil

Professor

Louisiana State University Health Sciences Center Shreveport

Eligibility Criteria

Inclusion Criteria

  • Patients presenting to the cardiac catheterization laboratory for coronary or peripheral angiography.
  • Females,Age\>40years

Exclusion Criteria

  • Inability to provide informed consent.
  • STelevationmyocardialinfarction.
  • Cardiogenicshock.
  • ABI \>1.4 (indicative of non-compressible vessel needing further evaluation to diagnose PAD), unless documented known PAD.
  • Non-atheroscleroticPAD(e.g.Buerger'sdisease).
  • Enrolment in another clinical trial with use of experimental therapeutic agents.

Outcomes

Primary Outcomes

Free Sulfide, Bound Sulfide and Acid Labile Sulfide

Time Frame: 1 year

Unit of Measure: nMol

Study Sites (1)

Loading locations...

Similar Trials